There’s little disputing that an off-the-shelf CAR-T cell therapy for cancer would provide flexibility and convenience over bespoke CAR-T therapies already in use. But can these experimental treatments induce the same kind of durable responses?
Allogene on Wednesday said its off-the-shelf CAR-T, called ALLO-501, maintained a 36% complete response rate at six months — an important measure of response durability — in patients with large B-cell lymphoma, a common and aggressive type of blood cancer.
About the Author Reprints
